MORRISVILLE, N.C., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it intends to offer and sell, subject to market and other conditions, ...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Novan, Inc. (“Novan” or the “Company”) (NASDAQ:NOVN) of the January 2, 2018 deadline to ...

DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering (the ...

Durham pharmaceutical company Novan filed for bankruptcy Monday as the publicly traded company prepares to be acquired. “They’re using the bankruptcy process as a way to sell their company,” said Jim ...

Novan Inc NOVN shares are trading lower after Ligand Pharmaceuticals Incorporated LGND announced that it has offered to acquire the company's assets. The deal value includes $15 million in cash and ...

As of May 11, 2023, the average one-year price target for Novan is 13.67. The forecasts range from a low of 9.09 to a high of $17.85. The average price target represents an increase of 1,068.21% from ...

Hello and welcome to the Novan Inc. Quarterly Update Conference Call and Webcast. As a reminder, our participants are currently in a listen-only mode. [Operator Instructions] Following the ...

DURHAM – Durham biotech Novan has filed for bankruptcy and struck a deal to sell most of its assets for $15 million. Novan (Nasdaq: NOVN) announced the news early Monday before stock markets opened.

DURHAM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (NOVN) and its wholly owned subsidiary, EPI Health, LLC (collectively, “the Company” or “Novan”), today announced that it has entered into a ...

The story for Novan as an operating entity is over. The company, which once specialized in medical dermatology, has ceased all active business and is now winding down its remaining corporate structure ...

Delisting of Securities of Nymox Pharmaceutical Corporation; Aridis Pharmaceuticals Inc.; Novan, Inc.; ViewRay, Inc.; 9 Meters Biopharma, Inc.; Nabriva Therapeutics ...